QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,301 signal articles · 518 in last 24h · 104,343 total before filter · latest 48m ago
518last 24h
2504last 7d
478● bullish (7d)
256● bearish (7d)
198publishers
AllMacro204Earnings1505M&A142Regulatory15Product7Analyst29
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Investing.com3d agoneutral
Why US stock bubbles keep bursting without derailing the wider market

Investing.com -- The U.S. stock market has repeatedly absorbed the collapse of speculative investment themes without suffering a broader downturn, but rising debt-financed spending on artificial intelligence could present a more serious threat, the Wall Street Journal reported.

Morgan Stanley's Amazon earnings verdict has a blind spot
TheStreet4d agoneutral
Morgan Stanley's Amazon earnings verdict has a blind spot

Amazon (AMZN) stock closed the July 31 trading session up 15.32% at $271.58, as it soared following the release of its second quarter (Q2) 2026 earnings report on July 30. The stock is up 17.66% year-to-date as of Saturday morning, August 1. Meanwhile, the SPDR S&P 500 index (SPY) is up about ...

3 Reasons WMG is Risky and 1 Stock to Buy Instead
StockStory4d agobullish
3 Reasons WMG is Risky and 1 Stock to Buy Instead

Warner Music Group currently trades at $29.22 per share and has shown little upside over the past six months, posting a small loss of 2.6%. The stock also fell short of the S&P 500’s 7.1% gain during that period.

Citi Says Investor Positioning Remains Resilient Despite Signs of Weakening Beneath the Surface
InvestorsHub4d agoneutral
Citi Says Investor Positioning Remains Resilient Despite Signs of Weakening Beneath the Surface

Global investor positioning continues to reflect a generally positive outlook, although underlying strength is becoming increasingly concentrated in a smaller number of markets and sectors, according to Citi strategists. The bank said recent market activity suggests investors remain constructive overall, but divergences across regions and asset classes indicate that risks are beginning to build beneath the surface.

PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?
StockStory4d agoneutral
PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?

Over the past six months, PepsiCo’s shares (currently trading at $144.08) have posted a disappointing 6.2% loss, well below the S&P 500’s 7.1% gain. This may have investors wondering how to approach the situation.

2 Reasons to Like FAST (and 1 Not So Much)
StockStory4d agoneutral
2 Reasons to Like FAST (and 1 Not So Much)

Fastenal has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 10.9% to $48.10 per share while the index has gained 7.1%.

Investing.com4d agoneutral
CTA Nasdaq de-risking appears largely complete: BofA

Investing.com -- Commodity trading advisers have largely unwound their Nasdaq-100 exposure, with the index’s short-term trend strength falling to just 13% against 53% for the S&P 500, BofA Securities said in a recent note.

Ralph Lauren (RL) Gains Ahead Of Earnings As Fair Value Stays In Focus
Simply Wall St.4d agoneutral
Ralph Lauren (RL) Gains Ahead Of Earnings As Fair Value Stays In Focus

What triggered the latest focus on Ralph Lauren stock Ralph Lauren (RL) is back in focus after its stock outpaced the S&P 500 with a 2.72% gain on a recent trading day, ahead of an earnings release scheduled for August 6, 2026. This price move comes as the company prepares to report quarterly results that are expected to show higher earnings and revenue compared with the prior year, while analyst consensus on earnings has seen slight downward revisions. See our latest analysis for Ralph...

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?
Simply Wall St.4d agoneutral
CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P 500. The stock is drawing attention as investors look ahead to its upcoming earnings report. See our latest analysis for CRISPR Therapeutics. At a share price of US$47.99, CRISPR Therapeutics has seen short term momentum cool, with a 30 day share price return down 13.72% and a 1 year total shareholder return down...